Evidence map›Paper›PMID 40301067›Full record

ArticleEndocrine journal2025

Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70

Jaeduk Yoshimura Noh, Natsuko Watanabe, Koichi Ito, Mika Tsuiki, Yuki Ishihara, Tetsuya Tagami, Ichiro Yamauchi, Ai Kozaki, Toshu Inoue, Bernard Rees Smith

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jaeduk Yoshimura NohDepartment of Internal Medicine, Ito Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7340-8603
Natsuko WatanabeDepartment of Internal Medicine, Ito Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2297-5004
Koichi ItoDepartment of Internal Medicine, Ito Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2341-3620
Mika TsuikiDepartment of Endocrinology and Metabolism, and Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Yuki IshiharaDepartment of Endocrinology and Metabolism, and Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.ORCID http://orcid.org/0000-0002-1036-3927
Tetsuya TagamiDepartment of Endocrinology and Metabolism, and Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.ORCID http://orcid.org/0000-0001-6266-3027
Ichiro YamauchiDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-4236-502X
Ai KozakiOlympia Eye Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4643-320X
Toshu InoueOlympia Eye Hospital, Tokyo, Japan.ORCID http://orcid.org/0009-0004-5443-4020
Bernard Rees SmithNippon Smith Yakuhin Kabushiki Kaisha, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9789-2484

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 1 dose-escalation study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of K1-70

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAutoantibodiesGraves DiseaseReceptors, ThyrotropinAdultAgedDose-Response Relationship, DrugEast Asian PeopleFemaleHumansJapanMaleMiddle AgedTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAutoantibodiesReceptors, ThyrotropinteprotumumabGraves’ diseaseGraves’ ophthalmopathyK1-70TMPharmacokineticsSafety profile

Identifiers

PMID40301067
PMCPMC12340244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.